Fatigue in multiple sclerosis: Associations with clinical,MRI and CSF parameters

Abstract

Background:

Damage of different brain structures has been related to fatigue. Alternatively, functional alterations of central nervous system (CNS) cells by the inflammatory milieu within the CNS may be responsible for the development of fatigue.

Aim:

To investigate the effect of structural brain damage and inflammatory cerebrospinal fluid (CSF) changes on fatigue in multiple sclerosis (MS).

Methods:

We determined the association of different clinical, CSF and magnetic resonance imaging (MRI) parameters with prevalence and severity of fatigue, as measured by the Fatigue Scale for Motor and Cognitive Functions in 68 early MS patients (discovery cohort). We validated our findings in two MS cohorts: the MRI validation cohort (N = 233) for the clinical and MRI parameters, and the CSF validation cohort (N = 81) for the clinical and CSF parameters.

Results:

Fatigue was associated with clinical disability. Fatigue did not correlate with any CSF parameter but correlated negatively with total and cortical grey matter volume. However, when controlling for Expanded Disability Status Scale (EDSS) in a multivariate model, these associations lost significance.

Conclusion:

Disability and disease duration best explain fatigue severity but none of the tested MRI or CSF parameter was reliably associated with fatigue.

Keywords

Multiple sclerosis demyelinating diseases fatigue magnetic resonance imaging flow cytometry cerebrospinal fluid

Get full access to this article

View all access options for this article.

References

Runia

Jafari

Siepman

. Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2015; 86: 543–546.

Kister

Bacon

Chamot

. Natural history of multiple sclerosis symptoms. Int J MS Care 2013; 15: 146–158.

Lebrun

Cohen

Clavelou

Evaluation of quality of life and fatigue in radiologically isolated syndrome. Rev Neurol 2016; 172: 392–395.

Cavallari

Palotai

Glanz

. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Mult Scler 2016; 22: 1841–1849.

Patejdl

Penner

Noack

. Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev 2016; 15: 210–220.

Bol

Duits

Lousberg

. Fatigue and physical disability in patients with multiple sclerosis: A structural equation modeling approach. J Behav Med 2010; 33: 355–363.

Morris

Berk

Galecki

. The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs). Mol Neurobiol 2014; 49: 741–756.

Bradley

Ford

Bansal

AS.

Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol 2013; 172: 73–80.

Maes

Bosmans

Kubera

Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: Inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers. Neuro Endocrinol Lett 2015; 36: 439–446.

10.

Brenu

Broadley

Nguyen

. A preliminary comparative assessment of the role of CD8+ T Cells in chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis. J Immunol Res 2016; 2016: 9064529.

11.

Fluge

Bruland

Risa

. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE 2011; 6: e26358.

12.

Dass

Bowman

Vital

. Reduction of fatigue in Sjogren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541–1544.

13.

De Flon

Laurell

Soderstrom

. Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Mult Scler; 23: 1249–1257.

14.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

15.

Penner

Raselli

Stocklin

. The Fatigue Scale for Motor and Cognitive Functions (FSMC): Validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009; 15: 1509–1517.

16.

Beck

Steer

Brown

GK.

Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.

17.

Marrie

Cohen

Stuve

. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler 2015; 21: 263–281.

18.

Cepok

Rosche

Grummel

. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 1667–1676.

19.

Shattuck

Mirza

Adisetiyo

. Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage 2008; 39: 1064–1080.

20.

Chard

Jackson

Miller

. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010; 32: 223–228.

21.

Bezzola

Merillat

Gaser

. Training-induced neural plasticity in golf novices. J Neurosci 2011; 31: 12444–12448.

22.

Treadway

Waskom

Dillon

. Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. Biol Psychiatry 2015; 77: 285–294.

23.

Muhlau

Buck

Forschler

. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: Support from structural MRI. Mult Scler 2013; 19: 1485–1492.

24.

Keihaninejad

Heckemann

Fagiolo

. A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010; 50: 1427–1437.

25.

Good

Johnsrude

Ashburner

. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001; 14: 21–36.

26.

Geurts

JJG

Calabrese

Fisher

. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11: 1082–1092.

27.

Henry

Shieh

Amirbekian

. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009; 282: 61–66.

28.

R-Core-Team. R: A language and environment for statistical computing, version 3.2.4. Vienna: R Foundation for Statistical Computing, 2016.

29.

Stuke

Flachenecker

Zettl

. Symptomatology of MS: Results from the German MS Registry. J Neurol 2009; 256: 1932–1935.

30.

Iriarte

Subira

Castro

Modalities of fatigue in multiple sclerosis: Correlation with clinical and biological factors. Mult Scler 2000; 6: 124–130.

31.

Simpson

Jr. Tan

Otahal

. Anxiety, depression and fatigue at 5-year review following CNS demyelination. Acta Neurol Scand 2016; 134: 403–413.

32.

Calabrese

Rinaldi

Grossi

. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 2010; 16: 1220–1228.

33.

Damasceno

Cendes

Atrophy of reward-related striatal structures in fatigued MS patients is independent of physical disability. Mult Scler 2016; 22: 822–829.

34.

Tedeschi

Dinacci

Lavorgna

. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci 2007; 263: 15–19.

35.

Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005; 11: 328–337.

36.

Figved

Klevan

Myhr

. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiat Scand 2005; 112: 463–468.

37.

Bamer

Johnson

Amtmann

. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 2008; 14: 1127–1130.

38.

Hasselmann

Bellmann-Strobl

Ricken

. Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. Mult Scler 2016; 22: 1476–1484.

39.

Finke

Schlichting

Papazoglou

. Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. Mult Scler 2015; 21: 925–934.

40.

Veauthier

Paul

Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med 2014; 15: 5–14.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.31 MB